Rising stem cell research and development is predicted to boost worldwide cell cryopreservation growth throughout the projection period. Bristol Myers Squibb, a worldwide biopharmaceutical corporation, announced in May 2022 that the European Commission had granted Marketing Authorization for Breyanzi, a CD19(B-lymphocyte antigen)-directed chimeric antigen receptor (CAR) T cell immunotherapy, for the treatment of adult patients with relapsed or refractory (R/R) diffuse large B-cell lymphoma (DLBCL), primary mediastinal large B-cell lymphoma (PMBCL), and follicular lymphoma grade 3B (FL3B) after two or more lines of systemic therapy. Breyanzi was granted Marketing Permission for usage in all European Union (EU) member countries. The market's growth is projected to be hampered by the adoption and development of alternative approaches.
According to Coherent Market Insights, The global
Cell Cryopreservation Market
size was valued at US$ 8,659.4 Million in 2022 and is expected to witness a CAGR of 22.4% over the forecast period (2022 – 2030).
Leading Companies in the Cell Cryopreservation Industry:
General Electric Company
General Electric Company operates as a high-tech industrial company in Europe, China, Asia, the Americas, the Middle East, and Africa. It offers gas and steam turbines, full balance of plant, upgrade, and service solutions, as well as data-leveraging software for power generation, industrial, government, and other customers. General Electric Company was incorporated in 1892 and is headquartered in Boston, Massachusetts.
Thermo Fisher Scientific Inc.
Thermo Fisher Scientific Inc. provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the United States and internationally. Thermo Fisher Scientific Inc. was founded in 1956 and is headquartered in Waltham, Massachusetts. In October 2018, Thermo Fisher Scientific Incacquired the Advanced Bioprocessing business from Becton, Dickinson and Company, a multinational medical technology company, for the expansion of its life sciences solutions segment. The acquisition expanded the bioproduction portfolio and enabled the company to bring new drugs into the market at a faster pace.
Miltenyi Biotec GmbH
Miltenyi Biotec is a medical services provider specializing in cell separation, cell labeling and cell analysis. The company was founded in 1989, headquartered in Germany. Lino Biotech acquired by Miltenyi Biotec on 17.03.2023
BioLife Solutions Inc.
